Ocrevus approved for use in Australia
17 July 2017
The Australian Therapeutic Goods Administration (TGA) has approved Ocrevus (ocrelizumab) for the treatment of multiple sclerosis in Australia.
The Australian Therapeutic Goods Administration (TGA) has approved Ocrevus (ocrelizumab) for the treatment of multiple sclerosis in Australia.
We are very pleased to announce a renewed commitment to MS Research Australia of $825,000 from the Commonwealth
In MS the immune system damages cells in the central nervous system (the brain, spinal cord or optic
Why do some people with relapsing remitting MS eventually transition to the secondary progressive phase but others do
Ms Katherine Sanders from Bond University QLD has recently completed her MS Research Australia PhD scholarship investigating the
MS Research Australia’s annual research grant program in 2016 enabled two promising researchers to undertake international travel with
For years the laws that govern fundraising in Australia have grown hopelessly outdated with charities facing heavy amounts
Paris is considered to be the “birthplace” of MS, where this debilitating disease was first discovered in 1868.
People with MS are more likely to suffer from depression than the general community, especially when newly diagnosed.